Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy.

Background Casitas B-lineage lymphoma proto-oncogene-b (CBLB) influences the threshold of T cell activation and controlling peripheral T cell tolerance. In the present study, we hypothesize that potentially functional single nucleotide polymorphisms (SNPs) in CBLB are associated with clinical outcomes in patients advanced non-small cell lung cancer (NSCLC) treated with the first-line chemotherapy. Methods We genotyped three SNPs (rs2305035, rs3772534 and rs9657904) at CBLB in 116 advanced NSCLC patients with progression free survival (PFS) data and 133 advanced NSCLC patients with overall survival (OS) data, and we assessed their associations, 95% confidence interval (CI), with clinical outcomes by using Cox proportional hazards regression analyses. In silico functional analysis was also performed for the SNPs under investigation. Results We found that associations between the three SNPs and PFS/OS were not significant in the overall NSCLC patients. The rs2305035 AA genotype was associated with a worse PFS in female patients and those of non-smokers or light smokers (95% CI, 1.14-11.81, P=0.030; 95% CI, 1.42-10.24, P=0.008; and 95% CI, 1.39-9.93, P=0.009; respectively), compared with the GG+AA genotypes. We also found that the rs9657904 CC genotype was significantly associated with a worse OS than TT + TC genotypes in male advanced NSCLC patients. Further in silico functional analysis revealed that the rs965704 T allele was significantly associated with lower mRNA expression levels of the CBLB gene. Conclusions Our findings identified two CBLB SNPs (rs2305035 and rs9657904) that were significantly associated with PFS and OS in several subgroups of Chinese advanced NSCLC patients after the first-line chemotherapy.

[1]  S. Steinberg,et al.  Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Gettinger,et al.  Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Liyi Zhang,et al.  Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy , 2016, Cancer science.

[4]  Hongliang Liu,et al.  Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. , 2016, Clinical lung cancer.

[5]  R. Muschel,et al.  Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma , 2016, Oncotarget.

[6]  K. Hirakawa,et al.  Tumour‐infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer , 2016, The British journal of surgery.

[7]  A. Bateman,et al.  Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma , 2016, Cancer Immunology, Immunotherapy.

[8]  T. Cotechini,et al.  Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis , 2016, Oncotarget.

[9]  Jinming Yu,et al.  Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. , 2015, Translational research : the journal of laboratory and clinical medicine.

[10]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[11]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[12]  D. Wolf,et al.  Modulation of Immune Cell Functions by the E3 Ligase Cbl-b , 2015, Front. Oncol..

[13]  Xiao-fei Wen,et al.  Silencing the expression of Cbl‐b enhances the immune activation of T lymphocytes against RM‐1 prostate cancer cells in vitro , 2014, Journal of the Chinese Medical Association : JCMA.

[14]  F. Garrido,et al.  Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. , 2014, Cancer research.

[15]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Cunningham,et al.  Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor , 2014, Medical Oncology.

[17]  A. Ullrich,et al.  The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells , 2014, Nature.

[18]  Navneet Singh,et al.  Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. , 2012, Journal of thoracic disease.

[19]  D. Talwar,et al.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. , 2011, European journal of cancer.

[20]  T. Merriman,et al.  A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets. , 2010, Human molecular genetics.

[21]  D. Galimberti,et al.  Association of the CBLB gene with multiple sclerosis: new evidence from a replication study in an Italian population , 2010, Journal of Medical Genetics.

[22]  J. Blattman,et al.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice. , 2010, The Journal of clinical investigation.

[23]  A. Gemma,et al.  F1000 highlights , 2010 .

[24]  Gianmauro Cuccuru,et al.  Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis , 2010, Nature Genetics.

[25]  Ye Zhang,et al.  Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation , 2010, Molecular and Cellular Biochemistry.

[26]  Ye Zhang,et al.  Ubiquitin ligase Cbl‐b sensitizes leukemia and gastric cancer cells to anthracyclines by activating the mitochondrial pathway and modulating Akt and ERK survival signals , 2009, FEBS letters.

[27]  M. Schmitz,et al.  Activation of T Cells: Releasing the Brakes by Proteolytic Elimination of Cbl-b , 2009, Science Signaling.

[28]  Scott M. Williams,et al.  The Genetic Structure and History of Africans and African Americans , 2009, Science.

[29]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[30]  R. Hodes,et al.  Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. , 2007, The Journal of clinical investigation.

[31]  R. Redon,et al.  Relative Impact of Nucleotide and Copy Number Variation on Gene Expression Phenotypes , 2007, Science.

[32]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[33]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[34]  C. Elly,et al.  Cbl-b, a RING-type E3 Ubiquitin Ligase, Targets Phosphatidylinositol 3-Kinase for Ubiquitination in T Cells* , 2001, The Journal of Biological Chemistry.

[35]  X-F Li,et al.  Cbl-b gene silencing in splenic T lymphocytes as a therapeutic strategy to target the prostate cancer RM-1 cell tumors in immune competent mice. , 2014, European review for medical and pharmacological sciences.

[36]  Nathaniel Rothman,et al.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. , 2004, Journal of the National Cancer Institute.